(Q36560963)

14 August 2017

1 reference

title

Incretins and the development of type 2 diabetes (English)

1 reference

14 August 2017

1 reference

Juris J Meier

1

1 reference

PubMed ID

16898571

14 August 2017

Michael A Nauck

series ordinal

2

1 reference

14 August 2017

1 June 2006

1 reference

14 August 2017

Current diabetes report

1 reference

14 August 2017

6

1 reference

14 August 2017

3

1 reference

14 August 2017

194-201

1 reference

https://scigraph.springernature.com/pub.10.1007/s11892-006-0034-7

14 August 2017

0 references

cites work

On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-006-0034-7

GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11892-006-0034-7

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

21 January 2018

1 reference

12 December 2020

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

1 reference

12 December 2020

Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure.

1 reference

12 December 2020

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus

1 reference

12 December 2020

Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance

1 reference

12 December 2020

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

1 reference

12 December 2020

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

12 December 2020

Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*

1 reference

12 December 2020

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

1 reference

12 December 2020

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

12 December 2020

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

12 December 2020

Preparation of highly active enterogastrone

1 reference

12 December 2020

The incretin concept today

1 reference

12 December 2020

Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

1 reference

12 December 2020

The pathogenesis of NIDDM involves a defective expression of the GIP receptor

1 reference

12 December 2020

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

1 reference

12 December 2020

The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

1 reference

12 December 2020

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

12 December 2020

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

1 reference

12 December 2020

Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

1 reference

12 December 2020

Hypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus

1 reference

12 December 2020

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects

1 reference

12 December 2020

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

1 reference

12 December 2020

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

1 reference

12 December 2020

Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.

1 reference

12 December 2020

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations

1 reference

12 December 2020

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2.

1 reference

12 December 2020

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

1 reference

12 December 2020

Glucose-dependent Insulinotropic Polypeptide Augmentation of Insulin Physiology or Pharmacology?

1 reference

12 December 2020

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

1 reference

12 December 2020

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

1 reference

12 December 2020

Gastric inhibitory polypeptide.

1 reference

12 December 2020

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1 reference

12 December 2020

Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

1 reference

12 December 2020

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

12 December 2020

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

1 reference

12 December 2020

Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39

1 reference

12 December 2020

Glucagon-like peptide 1 (GLP-1): a potent gut hormone with a possible therapeutic perspective.

1 reference

12 December 2020

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1 reference

12 December 2020

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

1 reference

12 December 2020

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

Exon duplication and divergence in the human preproglucagon gene

1 reference

12 December 2020

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

12 December 2020

Identification of the intestinal cell storing gastric inhibitory peptide

1 reference

12 December 2020

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Pancreatic and intestinal processing of proglucagon in man.

1 reference

12 December 2020

Immunoreactive gastric inhibitory polypeptide

1 reference

12 December 2020

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

12 December 2020

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype

1 reference

12 December 2020

Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance

1 reference

12 December 2020

Disturbances of the entero-insular axis

1 reference

12 December 2020

Glucagon-like peptide 1 regulates sequential and compound exocytosis in pancreatic islet beta-cells

1 reference

12 December 2020

A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells

1 reference

12 December 2020

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

1 reference

12 December 2020

New developments in the incretin concept

1 reference

12 December 2020

To be or not to be--an incretin or enterogastrone?

1 reference

12 December 2020

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

1 reference

12 December 2020

What are 'physiological' plasma GIP levels in man after intravenous infusion of porcine GIP?

1 reference

12 December 2020

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

12 December 2020

The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.

1 reference

12 December 2020

10.1007/S11892-006-0034-7

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16898571